Elizabeth E. Reed - 31 Jan 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Legal Officer and GC
Signature
/s/ Elizabeth E. Reed
Issuer symbol
TVTX
Transactions as of
31 Jan 2026
Net transactions value
-$230,461
Form type
4
Filing time
03 Feb 2026, 21:30:06 UTC
Previous filing
21 Jan 2026
Next filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
REED ELIZABETH E Chief Legal Officer and GC C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed 03 Feb 2026 0001283303

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +25,110 +28% $0.000000 115,380 31 Jan 2026 Direct F1
transaction TVTX Common Stock Sale $230,461 -7,175 -6.2% $32.12 108,205 03 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Award $0 +66,960 $0.000000 66,960 31 Jan 2026 Common Stock 66,960 $33.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.